Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
Abstract Background This study aimed to compare the feasibility of nab‐paclitaxel plus platinum‐based chemotherapy (nabTP) versus paclitaxel plus platinum‐based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable esophageal squamous cell carcin...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14795 |
| _version_ | 1827999964143288320 |
|---|---|
| author | Yafan Yang Haomiao Li Xiankai Chen Jianjun Qin Yong Li Yaxing Shen Ruixiang Zhang Xiaozheng Kang Zhen Wang Qingfeng Zheng Peng Luo Yin Li Jie He |
| author_facet | Yafan Yang Haomiao Li Xiankai Chen Jianjun Qin Yong Li Yaxing Shen Ruixiang Zhang Xiaozheng Kang Zhen Wang Qingfeng Zheng Peng Luo Yin Li Jie He |
| author_sort | Yafan Yang |
| collection | DOAJ |
| description | Abstract Background This study aimed to compare the feasibility of nab‐paclitaxel plus platinum‐based chemotherapy (nabTP) versus paclitaxel plus platinum‐based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable esophageal squamous cell carcinoma (ESCC). Methods Between April 2019 and March 2022, we identified ESCC patients who received neoadjuvant immunotherapy with both nabTP (n = 213) and TP (n = 98) at our institution and Henan Cancer Hospital. The patients in the ICIs‐nabTP and ICIs‐TP groups were pair‐matched (1:1) for tumor location, sex, smoking, drinking, clinical T and N stage. The primary endpoint was the hazard of 30‐day major postoperative complications. Second, logistic models were applied to estimate the risk factors for pathological complete response (pCR) rate. Results All patients underwent esophagectomy with R0 resection. A statistically significant increase in the risk of developing major pulmonary (odds ratio [OR], 1.182; 95% confidence interval [CI]: 0.530–2.635; p = 0.683), anastomotic (OR, 1.881; 95% CI: 0.607–5.830; p = 0.267), cardiac (OR, 1.000; 95% CI: 0.426–2.349; p = 1.000) complications after neoadjuvant immunotherapy plus nabTP was not observed. The median interval to surgery was 39 days in the ICIs‐nabTP group versus 44 days in the ICIs‐TP group (p = 0.119). There was no 30‐day mortality in each group. However, there was a slight difference in the 30‐day readmission rate (p = 0.043) and the incidence of hydropneumothorax (p = 0.027) between the two groups. The pCR rates of the ICIs‐nabTP and ICIs‐TP group were 36.7 and 21.4%, respectively (p = 0.018). Conclusions It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC. |
| first_indexed | 2024-04-10T06:06:40Z |
| format | Article |
| id | doaj.art-d62c78f584e24031bfc531272f042979 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-10T06:06:40Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-d62c78f584e24031bfc531272f0429792023-03-03T00:09:57ZengWileyThoracic Cancer1759-77061759-77142023-03-0114770070810.1111/1759-7714.14795Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinomaYafan Yang0Haomiao Li1Xiankai Chen2Jianjun Qin3Yong Li4Yaxing Shen5Ruixiang Zhang6Xiaozheng Kang7Zhen Wang8Qingfeng Zheng9Peng Luo10Yin Li11Jie He12Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery Henan Cancer Hospital Zhengzhou City ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaAbstract Background This study aimed to compare the feasibility of nab‐paclitaxel plus platinum‐based chemotherapy (nabTP) versus paclitaxel plus platinum‐based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable esophageal squamous cell carcinoma (ESCC). Methods Between April 2019 and March 2022, we identified ESCC patients who received neoadjuvant immunotherapy with both nabTP (n = 213) and TP (n = 98) at our institution and Henan Cancer Hospital. The patients in the ICIs‐nabTP and ICIs‐TP groups were pair‐matched (1:1) for tumor location, sex, smoking, drinking, clinical T and N stage. The primary endpoint was the hazard of 30‐day major postoperative complications. Second, logistic models were applied to estimate the risk factors for pathological complete response (pCR) rate. Results All patients underwent esophagectomy with R0 resection. A statistically significant increase in the risk of developing major pulmonary (odds ratio [OR], 1.182; 95% confidence interval [CI]: 0.530–2.635; p = 0.683), anastomotic (OR, 1.881; 95% CI: 0.607–5.830; p = 0.267), cardiac (OR, 1.000; 95% CI: 0.426–2.349; p = 1.000) complications after neoadjuvant immunotherapy plus nabTP was not observed. The median interval to surgery was 39 days in the ICIs‐nabTP group versus 44 days in the ICIs‐TP group (p = 0.119). There was no 30‐day mortality in each group. However, there was a slight difference in the 30‐day readmission rate (p = 0.043) and the incidence of hydropneumothorax (p = 0.027) between the two groups. The pCR rates of the ICIs‐nabTP and ICIs‐TP group were 36.7 and 21.4%, respectively (p = 0.018). Conclusions It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC.https://doi.org/10.1111/1759-7714.14795immunotherapynab‐paclitaxelPaclitaxel esophageal squamous cell carcinoma |
| spellingShingle | Yafan Yang Haomiao Li Xiankai Chen Jianjun Qin Yong Li Yaxing Shen Ruixiang Zhang Xiaozheng Kang Zhen Wang Qingfeng Zheng Peng Luo Yin Li Jie He Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma Thoracic Cancer immunotherapy nab‐ paclitaxel Paclitaxel esophageal squamous cell carcinoma |
| title | Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma |
| title_full | Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma |
| title_fullStr | Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma |
| title_full_unstemmed | Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma |
| title_short | Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma |
| title_sort | comparison of neoadjuvant nab paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma |
| topic | immunotherapy nab‐ paclitaxel Paclitaxel esophageal squamous cell carcinoma |
| url | https://doi.org/10.1111/1759-7714.14795 |
| work_keys_str_mv | AT yafanyang comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT haomiaoli comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT xiankaichen comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT jianjunqin comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT yongli comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT yaxingshen comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT ruixiangzhang comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT xiaozhengkang comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT zhenwang comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT qingfengzheng comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT pengluo comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT yinli comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma AT jiehe comparisonofneoadjuvantnabpaclitaxelplusimmunotherapyversuspaclitaxelplusimmunotherapyforesophagealsquamouscellcarcinoma |